Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats (CROSBI ID 214223)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Macan, Marija ; Vukšić, Antonija ; Žunec, Suzana ; Konjevoda, Paško ; Lovrić, Jasna ; Kelava, Marta ; Štambuk, Nikola ; Vrkić, Nada ; Bradamante, Vlasta Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats // Pharmacological reports, 67 (2015), 907-913. doi: 10.1016/j.pharep.2015.02.005

Podaci o odgovornosti

Macan, Marija ; Vukšić, Antonija ; Žunec, Suzana ; Konjevoda, Paško ; Lovrić, Jasna ; Kelava, Marta ; Štambuk, Nikola ; Vrkić, Nada ; Bradamante, Vlasta

engleski

Effects of simvastatin on malondialdehyde level and esterase activity in plasma and tissue of normolipidemic rats

We investigated the possible non-lipid effects of simvastatin (SIMV) on paraoxonase 1 (PON1) and butyrylcholinesterase (BuChE) activity, as well as on malondialdehyde (MDA) levels in normolipidemic rats. Two experimental groups of Wistar rats (10 mg/kg/day of SIMV) and two control groups (saline) underwent a 21-day treatment period (TP). On the 22nd day one experimental and one control group of rats were sacrificed. The remaining groups of animals were sacrificied on the 32nd day of the study (10-day after-treatment period (AT)). Blood samples and slices of liver, heart, kidney, and brain tissue were obtained for the measurement of PON1 and BuChE activity and levels of MDA. Data were analyzed by means of t-test for independent samples. P values ≤ 0.05 were considered as statistically significant. SIMV caused a significant decrease of serum and liver PON1 activity (18%-24%, p≤0.05) and MDA concentrations in the plasma, heart, liver, kidney, and brain (9-40%, p≤0.05), while plasma and liver BuChE activity increased by 29% (p≤0.05) and 18%, respectively. All effects of SIMV were largely diminished following AT. The exception was MDA, which remained significantly decreased in plasma and all tissues analyzed. Simvastatin significantly decreased PON1 activity and MDA levels and increased BuChE activity. We suggest that the decrease of MDA levels is a beneficial therapeutic effect of SIMV, for example in cardiovascular disorders, while the increase of BuChE activity, especially in the brain, may be a potential adverse effect in patients with Alzheimer disease.

simvastatin; paraoxonase 1; butyrylcholinesterase; malondialdehyde

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

67

2015.

907-913

objavljeno

1734-1140

2299-5684

10.1016/j.pharep.2015.02.005

Povezanost rada

Temeljne medicinske znanosti, Farmacija

Poveznice
Indeksiranost